ADVM
Price
$2.48
Change
-$0.10 (-3.88%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
53.9M
OCUL
Price
$9.46
Change
+$0.27 (+2.94%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
1.46B
46 days until earnings call
Interact to see
Advertisement

ADVM vs OCUL

Header iconADVM vs OCUL Comparison
Open Charts ADVM vs OCULBanner chart's image
Adverum Biotechnologies
Price$2.48
Change-$0.10 (-3.88%)
Volume$4.6K
Capitalization53.9M
Ocular Therapeutix
Price$9.46
Change+$0.27 (+2.94%)
Volume$86.28K
Capitalization1.46B
ADVM vs OCUL Comparison Chart in %
Loading...
ADVM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADVM vs. OCUL commentary
Jun 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADVM is a StrongBuy and OCUL is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 27, 2025
Stock price -- (ADVM: $2.58 vs. OCUL: $9.19)
Brand notoriety: ADVM and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADVM: 61% vs. OCUL: 141%
Market capitalization -- ADVM: $53.9M vs. OCUL: $1.46B
ADVM [@Biotechnology] is valued at $53.9M. OCUL’s [@Biotechnology] market capitalization is $1.46B. The market cap for tickers in the [@Biotechnology] industry ranges from $312.97B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADVM’s FA Score shows that 0 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • ADVM’s FA Score: 0 green, 5 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, both ADVM and OCUL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADVM’s TA Score shows that 5 TA indicator(s) are bullish while OCUL’s TA Score has 7 bullish TA indicator(s).

  • ADVM’s TA Score: 5 bullish, 4 bearish.
  • OCUL’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, OCUL is a better buy in the short-term than ADVM.

Price Growth

ADVM (@Biotechnology) experienced а +12.66% price change this week, while OCUL (@Biotechnology) price change was +10.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.00%. For the same industry, the average monthly price growth was +32.55%, and the average quarterly price growth was +15.13%.

Reported Earning Dates

ADVM is expected to report earnings on Apr 15, 2025.

OCUL is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+2.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($1.46B) has a higher market cap than ADVM($53.9M). OCUL YTD gains are higher at: 7.611 vs. ADVM (-44.754). ADVM has higher annual earnings (EBITDA): -154.84M vs. OCUL (-176.35M). OCUL has more cash in the bank: 350M vs. ADVM (83.1M). OCUL has less debt than ADVM: OCUL (76.2M) vs ADVM (93.2M). OCUL has higher revenues than ADVM: OCUL (59.6M) vs ADVM (1M).
ADVMOCULADVM / OCUL
Capitalization53.9M1.46B4%
EBITDA-154.84M-176.35M88%
Gain YTD-44.7547.611-588%
P/E RatioN/AN/A-
Revenue1M59.6M2%
Total Cash83.1M350M24%
Total Debt93.2M76.2M122%
FUNDAMENTALS RATINGS
ADVM vs OCUL: Fundamental Ratings
ADVM
OCUL
OUTLOOK RATING
1..100
8014
VALUATION
overvalued / fair valued / undervalued
1..100
40
Fair valued
54
Fair valued
PROFIT vs RISK RATING
1..100
10088
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
6540
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ADVM's Valuation (40) in the Biotechnology industry is in the same range as OCUL (54) in the Pharmaceuticals Other industry. This means that ADVM’s stock grew similarly to OCUL’s over the last 12 months.

OCUL's Profit vs Risk Rating (88) in the Pharmaceuticals Other industry is in the same range as ADVM (100) in the Biotechnology industry. This means that OCUL’s stock grew similarly to ADVM’s over the last 12 months.

OCUL's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as ADVM (99) in the Biotechnology industry. This means that OCUL’s stock grew similarly to ADVM’s over the last 12 months.

OCUL's Price Growth Rating (40) in the Pharmaceuticals Other industry is in the same range as ADVM (65) in the Biotechnology industry. This means that OCUL’s stock grew similarly to ADVM’s over the last 12 months.

OCUL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as ADVM (100) in the Biotechnology industry. This means that OCUL’s stock grew similarly to ADVM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADVMOCUL
RSI
ODDS (%)
Bullish Trend 7 days ago
90%
Bearish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
80%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 7 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ADVM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ALVIX10.45N/A
N/A
American Century Focused Lg Cap Val Inv
FPURX25.22N/A
N/A
Fidelity Puritan
LSVAX18.60N/A
N/A
Loomis Sayles Small Cap Value Admin
SMEYX16.18N/A
N/A
Invesco Small Cap Equity Y
SBHCX12.13N/A
N/A
Segall Bryant & Hamill Small Cap Cre Ret

ADVM and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADVM has been loosely correlated with CCCC. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ADVM jumps, then CCCC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADVM
1D Price
Change %
ADVM100%
+1.57%
CCCC - ADVM
47%
Loosely correlated
-1.28%
IMNM - ADVM
47%
Loosely correlated
-2.69%
XENE - ADVM
45%
Loosely correlated
-1.27%
ATXS - ADVM
45%
Loosely correlated
-1.91%
OCUL - ADVM
44%
Loosely correlated
+1.10%
More

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
+1.10%
EYPT - OCUL
56%
Loosely correlated
+14.81%
DNLI - OCUL
55%
Loosely correlated
+0.35%
RNA - OCUL
51%
Loosely correlated
+0.10%
IMVT - OCUL
49%
Loosely correlated
-1.56%
RVMD - OCUL
49%
Loosely correlated
-4.05%
More